Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database.

Details

Serval ID
serval:BIB_0A89637C6063
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database.
Journal
European journal of cancer
Author(s)
Margalit O., Harmsen W.S., Shacham-Shmueli E., Voss M.M., Boursi B., Wagner A.D., Cohen R., Olswold C.L., Saltz L.B., Goldstein D.A., Hurwitz H., Tebbutt N.C., Kabbinavar F.F., Adams R.A., Chibaudel B., Grothey A., Yoshino T., Zalcberg J., de Gramont A., Shi Q., Lenz H.J.
ISSN
1879-0852 (Electronic)
ISSN-L
0959-8049
Publication state
Published
Issued date
02/11/2022
Peer-reviewed
Oui
Volume
178
Pages
162-170
Language
english
Notes
Publication types: Journal Article
Publication Status: aheadofprint
Abstract
Previous studies suggest a possible sex-specific response to bevacizumab in metastatic colorectal carcinoma (mCRC), showing a benefit in males, while the effect in females is less significant.
Data from 3369 patients with mCRC enrolled on four first-line randomised trials testing chemotherapy with or without bevacizumab (2000-2007) were pooled. Association between sex and progression-free survival and overall survival (OS) was evaluated by stratified Cox regression model, adjusted for potential confounders. Predictive value was evaluated by interaction effect between sex and treatment. In a pre-planned secondary analysis, analyses were stratified using an age cut point of 60 years to evaluate the possible role of menopausal-related effects.
Bevacizumab was associated with an improved median OS in males and females, with a 2.3- and 0.6-months benefit, respectively. Stratified by age, bevacizumab resulted in improved OS in males at both age categories. In females at or above the age of 60 (n = 731), bevacizumab resulted in improved OS. However, in females below the age of 60 (n = 634), OS benefit did not reach statistical significance (adjusted hazard ratio = 0.94, 95% confidence interval 0.74-1.20).
Our results confirmed the OS benefit from the addition of bevacizumab to first-line chemotherapy in mCRC in both sexes. Among females, the benefit was less than 1 month. For females under the age of 60, there was no survival benefit. These findings could be used to relieve financial toxicity or be redistributed within healthcare systems for other health-related purposes.
Keywords
ARCAD, Age, Bevacizumab, Colorectal carcinoma, Metastatic, Sex
Pubmed
Create date
05/12/2022 15:03
Last modification date
04/01/2023 6:49
Usage data